Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Robbrecht D, Grob JJ, Bechter O, Simonelli M, Doger B, Borbath I, Butler MO, Cheng T, Romano PM, Pons-Tostivint E, Di Nicola M, Curigliano G, Ryu MH, Rodriguez-Vida A, Schadendorf D, Garralda E, Abbadessa G, Demers B, Amrate A, Wang H, Lee JS, Pomponio R, Wang R. Robbrecht D, et al. Clin Transl Sci. 2024 Feb;17(2):e13736. doi: 10.1111/cts.13736. Clin Transl Sci. 2024. PMID: 38362837 Free PMC article. Clinical Trial.
[Mesenteric panniculitis: variable presentations].
Robbrecht DG, Alidjan F, Eikemans B, Haans DA, van Guldener C, van Wijngaarden P. Robbrecht DG, et al. Ned Tijdschr Geneeskd. 2012;155(25):A4555. Ned Tijdschr Geneeskd. 2012. PMID: 22748362 Dutch.
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW. van der Wijngaart H, et al. Clin Cancer Res. 2021 Nov 15;27(22):6106-6114. doi: 10.1158/1078-0432.CCR-21-1104. Epub 2021 Sep 2. Clin Cancer Res. 2021. PMID: 34475104
[Symptomatic hypocalcaemia on denosumab use].
Baptista Lopes V, Robbrecht D, van Thiel S, van Guldener C. Baptista Lopes V, et al. Among authors: robbrecht d. Ned Tijdschr Geneeskd. 2013;157(29):A6159. Ned Tijdschr Geneeskd. 2013. PMID: 23859106 Dutch.
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.
Steeghs N, Gomez-Roca C, Rohrberg KS, Mau-Sørensen M, Robbrecht D, Tabernero J, Ahmed S, Rodriguez-Ruiz ME, Ardeshir C, Schmid D, Sleiman N, Watson C, Piper-Lepoutre H, Dejardin D, Evers S, Boetsch C, Charo J, Teichgräber V, Melero I. Steeghs N, et al. Among authors: robbrecht d. Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-3567. Online ahead of print. Clin Cancer Res. 2024. PMID: 38630781
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.
Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland SØ, Guren TK, Aftimos P, Liberg D, Svedman C, Thorsson L, Steeghs N, Awada A. Robbrecht D, et al. Br J Cancer. 2022 Apr;126(7):1010-1017. doi: 10.1038/s41416-021-01657-7. Epub 2021 Dec 13. Br J Cancer. 2022. PMID: 34903842 Free PMC article. Clinical Trial.
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko JH, Verlingue L, de Miguel M, Pasanen A, Robbrecht D, Skytta T, Iivanainen S, Shetty S, Ma YT, Graham DM, Arora SP, Jaakkola P, Yap C, Xiang Y, Mandelin J, Karvonen MK, Jalkanen J, Karaman S, Koivunen JP, Minchom A, Hollmén M, Bono P. Rannikko JH, et al. Among authors: robbrecht d. Cell Rep Med. 2023 Dec 19;4(12):101307. doi: 10.1016/j.xcrm.2023.101307. Epub 2023 Dec 5. Cell Rep Med. 2023. PMID: 38056464 Free PMC article. Clinical Trial.
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial.
Virtakoivu R, Rannikko JH, Viitala M, Vaura F, Takeda A, Lönnberg T, Koivunen J, Jaakkola P, Pasanen A, Shetty S, de Jonge MJA, Robbrecht D, Ma YT, Skyttä T, Minchom A, Jalkanen S, Karvonen MK, Mandelin J, Bono P, Hollmén M. Virtakoivu R, et al. Among authors: robbrecht d. Clin Cancer Res. 2021 Aug 1;27(15):4205-4220. doi: 10.1158/1078-0432.CCR-20-4862. Epub 2021 Jun 2. Clin Cancer Res. 2021. PMID: 34078651 Free PMC article. Clinical Trial.
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.
Vermunt MAC, Robbrecht DGJ, Devriese LA, Janssen JM, Thijssen B, Keessen M, van Eijk M, Kessels R, Eskens FALM, Beijnen JH, Mehra N, Bergman AM. Vermunt MAC, et al. Cancer Rep (Hoboken). 2021 Aug;4(4):e1367. doi: 10.1002/cnr2.1367. Epub 2021 Mar 12. Cancer Rep (Hoboken). 2021. PMID: 33709626 Free PMC article. Clinical Trial.
30 results